ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2522

Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event

Kerem Abacar1, Ayşe Elif Boncukcuoğlu1, Aysun Aksoy2, Derya Kocakaya1, Çagatay Cimşit1, Haner Direskeneli3 and Fatma Alibaz Öner3, 1Marmara University, istanbul, Turkey, 2Alaaddin Keykubat University, Antalya, Turkey, 3Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey

Meeting: ACR Convergence 2024

Keywords: Behçet's Syndrome, pulmonary, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome. In this study, we aimed to evaluate the clinical features, course and factors affecting the recurrence risk of BD-associated PAI.

Methods: BD patients followed up between 1990-2022 were included. All data were acquired from the patient charts. Findings were classified according to the vascular structures in which thrombotic or aneurysmal formation was detected. Factors affecting the risk of relapses were determined using multivariate Cox regression analysis.

Results: Among 1350 BD patients, 110 (8.1%) had PAI. The mean age (SD) of patients with PAI was 42.4 (11.6) years, and the male/female ratio was 2.2 (76/34). Thirty-two (29.1%) of 110 patients were asymptomatic. (Figure 1) Symptomatic patients with PAI were significantly older (p=0.031), and female gender (p=0.001) and recurrence rates (p=0.019) were higher than asymptomatic patients with PAI. Pulmonary arterial thrombosis (PAT) was seen in 104 (94.5%) and aneurysms in 9 (6.6%) patients. PAI relapses were observed at least once in 31 (28.2%) patients. In multivariate analysis, the Cox regression model was significant (p=0.013) and not starting anticoagulants (HR 4.36, 95% CI 1.14-24.1), p=0.042), independently increased the PAI relapse risk. (Table 1)

Conclusion:
PAT is the main presentation type of PAI in BD while aneurysmatic formation is rare. In one-third of patients with PAI, relapses develop during follow-up despite immunosuppressive treatment. When added to immunosuppressive treatment, anticoagulant therapy significantly decreases the relapse rate in BD patients with PAI.

Supporting image 1

Figure 1. The distribution of patients is classified according to symptom status, size of involved vessels and acute phase reactant levels at the time of diagnosis of pulmonary arterial involvement

Supporting image 2

Table 1. Factors associated with pulmonary thrombi relapses in Behcet’s disease patients with pulmonary arterial involvement


Disclosures: K. Abacar: None; A. Boncukcuoğlu: None; A. Aksoy: None; D. Kocakaya: None; Ç. Cimşit: None; H. Direskeneli: AbbVie/Abbott, 12, Educational grants, Amgen, 12, Educational grants, Roche, 12, Educational grants, UCB, 12, Educational grants; F. Alibaz Öner: AbbVie/Abbott, 12, Educational grants, Amgen, 12, Educational grants, Roche, 12, Educational grants, UCB, 12, Educational grants.

To cite this abstract in AMA style:

Abacar K, Boncukcuoğlu A, Aksoy A, Kocakaya D, Cimşit Ç, Direskeneli H, Alibaz Öner F. Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/anticoagulant-treatment-may-decrease-the-relapse-rate-in-pulmonary-arterial-involvement-of-behcets-disease-when-added-after-the-first-event/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anticoagulant-treatment-may-decrease-the-relapse-rate-in-pulmonary-arterial-involvement-of-behcets-disease-when-added-after-the-first-event/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology